Bromide

Bromide

SCHEMBL580087

Br.CCCCCCCCCCCCCCCCCN

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 9/20 1.00
TSHR P16473 3/20 0.93
MEN1 O00255 1/20 0.93
KMT2A Q03164 1/20 0.93
ALDH1A1 P00352 1/20 0.93
EPHX1 P07099 1/20 0.93
CA12 O43570 2/20 0.57
CA1 P00915 2/20 0.57
CA2 P00918 2/20 0.57
CA3 P07451 2/20 0.57
CA4 P22748 2/20 0.57
CA6 P23280 2/20 0.57
CA5A P35218 2/20 0.57
CA7 P43166 2/20 0.57
CA9 Q16790 2/20 0.57
CA14 Q9ULX7 2/20 0.57
CA5B Q9Y2D0 2/20 0.57
THRB P10828 1/20 0.57
LMNA P02545 1/20 0.57
BLM P54132 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL2444301 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1
Bromide SCHEMBL3895282 1.00
Dodecylamine SCHEMBL129158 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1
Pentadecylamine SCHEMBL3049228 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1
Bromide SCHEMBL1257604 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1
Hexadecylamine SCHEMBL126964 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1
Bromide SCHEMBL3106064 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1
Bromide SCHEMBL5557202 1.00
Bromide SCHEMBL11380806 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1
Icosylamine SCHEMBL609205 1.00 DNM1 (1.00) DNM1TSHRMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250344704-A1 SEED TREATMENT METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS AND YIELD ANDES AG INC (US) 2025-11-13 US claimed
US-20250288594-A1 PHARMACEUTICAL DOSAGE FORMS AND METHODS OF USE EMALEX BIOSCIENCES, INC. 2025-09-18 US claimed
EP-4527499-A1 A CATALYST FOR HYDROGENATION OF UNSATURATED HYDROCARBONS AND A METHOD FOR PREPARATION THEREOF Indian Oil Corporation Limited (IN) 2025-03-26 EP claimed
US-20250091037-A1 CATALYST FOR HYDROGENATION OF UNSATURATED HYDROCARBONS AND A METHOD FOR PREPARATION THEREOF INDIAN OIL CORPORATION LIMITED (IN) 2025-03-20 US claimed
CN-114050273-B Modified graphene oxide, composite material, GDL and preparation method thereof 东风汽车集团股份有限公司 2022-11-01 CN claimed
CN-112974796-B Composite structure of single silver nanowire and preparation method and application thereof 南京大学 2022-06-21 CN claimed
US-20220144716-A1 SEED TREATMENT METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS AND YIELD ANDES AG, INC. 2022-05-12 US claimed
CN-114449895-A Novel seed treatment methods and compositions for improving plant traits and yield 安第斯农业公司 2022-05-06 CN claimed
EP-3956276-A1 NOVEL SEED TREATMENT METHODS AND COMPOSITIONS FOR IMPROVING PLANT TRAITS AND YIELD Andes Ag, Inc. (US) 2022-02-23 EP claimed
CN-114050273-A Modified graphene oxide, composite material, GDL and preparation method thereof 东风汽车集团股份有限公司 2022-02-15 CN claimed
US-5597560-A NON-STEROID ANTIINFLAMMATORY AGENT AND ANTIBIOTIC MIXTURE; SHELF LIFE LABORATORIOS CUSI, S.A. (ES) 1997-01-28 US claimed
EP-0661055-A1 Pharmaceutical formulation containing clobetasone and tobramycin and applications thereof LABORATORIOS CUSI, S.A. (ES) 1995-07-05 EP claimed
EP-0592348-A1 Pharmaceutical formulation comprised of polymyxin-trimethoprim and an anti-inflammatory drug for ophthalmic and optic topical use LABORATORIOS CUSI, S.A. (ES) 1994-04-13 EP claimed
US-4680235-A Recording material for ink jet printing RICOH COMPANY, LTD. (JP) 1987-07-14 US claimed
US-4634580-A PRE-REDUCTION OF IRON URANIUM PECHINEY (FR) 1987-01-06 US claimed
US-4469685-A PLANT EXTRACTS THE KITASATO INSTITUTE (JP) 1984-09-04 US claimed
US-4456597-A SOLVENT EXTRACTION WITH WATER, AND FILTRATION THE KITASATO INSTITUTE (JP) 1984-06-26 US claimed
US-4442087-A EXTRACT OF ARTEMISIA THE KITASATO INSTITUTE (JP) 1984-04-10 US claimed
US-4419349-A PLANT EXTRACTS THE KITASATO INSTITUTE (JP) 1983-12-06 US claimed
EP-0061793-A1 Method for preparing a chromogen reactive for determining the serum iron concentration and binding power, and the chromogen reactive obtained thereby CHEMICAL LABORATORIES S.r.l. (IT) 1982-10-06 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250288594-A1 PHARMACEUTICAL DOSAGE FORMS AND METHODS OF USE MC2R, PTGDR, HTR5A DNM1 2489/4885TSHR 135/4885MEN1 1411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.